

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | | | | | | | | | | | |
|--|--------------------------|---|------------------------|----|---------|--------------------------|----|---------|-------------------------|----|---------|------------------------|----|---|
| (51) International Patent Classification 4 : C12N 7/00, 5/00, 1/00 C12Q 1/70, 1/68, G01N 33/535 C07H 15/12, A61K 37/02, 37/04 C07K 13/00, C07G 7/00 C07K 7/00 | A1 | (11) International Publication Number: WO 90/00597 (43) International Publication Date: 25 January 1990 (25.01.90) | | | | | | | | | | | | |
| (21) International Application Number: PCT/US89/02817 (22) International Filing Date: 28 June 1989 (28.06.89) (30) Priority data: <table border="0" style="width: 100%;"><tr><td style="width: 30%;">215,728</td><td style="width: 40%;">6 July 1988 (06.07.88)</td><td style="width: 30%;">US</td></tr><tr><td>228,334</td><td>4 August 1988 (04.08.88)</td><td>US</td></tr><tr><td>334,701</td><td>6 April 1989 (06.04.89)</td><td>US</td></tr><tr><td>350,570</td><td>11 May 1989 (11.05.89)</td><td>US</td></tr></table> (71) Applicants: GENELABS INCORPORATED [US/US]; 505 Penobscot Drive, Redwood City, CA 94063 (US). THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS [US/US]; Washington, DC 20231 (US). | | 215,728 | 6 July 1988 (06.07.88) | US | 228,334 | 4 August 1988 (04.08.88) | US | 334,701 | 6 April 1989 (06.04.89) | US | 350,570 | 11 May 1989 (11.05.89) | US | (72) Inventors: REYES, Gregory, R. ; 2112 St. Frances Drive, Palo Alto, CA 94303 (US). BRADLEY, Daniel, W. ; 2938 Kelly Court, Lawrenceville, GA 30244 (US). RABIN, Linda ; 112 Westgate, Redwood City, CA 94061 (US). FRY, Kirk, E. ; 2604 Ross Road, Palo Alto, CA 94303 (US). (74) Agent: NEELEY, Richard, L.; Leydig, Voit & Mayer, 350 Cambridge Avenue, Suite 200, Palo Alto, CA 94306 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i> |
| 215,728 | 6 July 1988 (06.07.88) | US | | | | | | | | | | | | |
| 228,334 | 4 August 1988 (04.08.88) | US | | | | | | | | | | | | |
| 334,701 | 6 April 1989 (06.04.89) | US | | | | | | | | | | | | |
| 350,570 | 11 May 1989 (11.05.89) | US | | | | | | | | | | | | |
| (54) Title: POST-TRANSFUSION, NON-A, NON-B HEPATITIS VIRUS AND ANTIGENS (57) Abstract <p>Purified virus particles, antigenes, antibodies reactive with viral antigenes, and a viral genetic material associated with non-A, non-B hepatitis are provided by the present invention. Cloned genetic material useful both in identifying intact virus particles of the invention and for use in diagnostic techniques and/or production of antigenes is also disclosed.</p> | | | | | | | | | | | | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria | ES | Spain | MG | Madagascar |
| AU | Australia | FI | Finland | ML | Mali |
| BB | Barbados | FR | France | MR | Mauritania |
| BE | Belgium | GA | Gabon | MW | Malawi |
| BF | Burkina Faso | GB | United Kingdom | NL | Netherlands |
| BG | Bulgaria | HU | Hungary | NO | Norway |
| BJ | Benin | IT | Italy | RO | Romania |
| BR | Brazil | JP | Japan | SD | Sudan |
| CA | Canada | KP | Democratic People's Republic of Korea | SE | Sweden |
| CF | Central African Republic | KR | Republic of Korea | SN | Senegal |
| CG | Congo | LI | Liechtenstein | SU | Soviet Union |
| CH | Switzerland | LK | Sri Lanka | TD | Chad |
| CM | Cameroon | LU | Luxembourg | TG | Togo |
| DE | Germany, Federal Republic of | MC | Monaco | US | United States of America |
| DK | Denmark | | | | |

5 **POST-TRANSFUSION, NON-A, NON-B HEPATITIS**
 VIRUS AND ANTIGENS

CROSS-REFERENCE TO RELATED APPLICATIONS

10

 This application is a continuation in part of
US Application Serial No. 350,570, filed May 11, 1989,
which is a continuation in part of US Application
Serial No. 334,701, filed April 6, 1989, which is a
15 continuation in part of US Application Serial No.
228,334, filed August 4, 1988, which is a continuation
in part of US Application Serial No. 215,728, filed
July 6, 1988, which is a continuation in part of US
Application Serial No. 846,757, filed April 1, 1986,
20 which disclosures are hereby incorporated herein by
reference.

INTRODUCTION

25 **Technical Field**

 This invention relates to virus associated
with post transfusion non-A, non-B (PT-NANB) hepatitis,
to PT-NANB antigens produced by recombinant processes,
and to products and processes associated with
30 vaccination against, diagnosis of, and prophylaxis of
PT-NANB hepatitis.

Background

 Acute viral hepatitis is a systemic infection
35 with predominant pathology affecting the liver. Five
types of viral agents which cause hepatitis are known
to exist: hepatitis A virus (HAV), hepatitis B virus
(HBV), post transfusion (PT) and enteric transmission
(ET), non-A, non-B (NANB) hepatitis agents, and the

HBV-associated delta virus. Specific viral agents have been associated with HAV, HBV, and delta virus. However, despite numerous publications reporting agents associated with PT-NANB hepatitis, there does not
5 appear to be any consensus that the etiologic agent has been identified. Harrison's Principals of Internal Medicine, 11th edition (1987), reports that there are at least two different blood-borne NANB hepatitis agents, although the virus(es) or virus antigens are
10 said not to have been identified definitively.

Routine screening of blood donors for anti-HBV antibody and HBV antigen (HBsAg) has decreased the incidence of hepatitis B after blood transfusion, but post-transfusion PT hepatitis due to infection with
15 NANB hepatitis agents is still a significant problem because of the lack of an acceptable serologic screening test to identify PT-NANB hepatitis agents. Identification of new viruses and the use of genetic information obtained from the viruses to produce
20 recombinant proteins that are safe for use in vaccines and diagnostics are major goals in the development of a safe blood supply.

Relevant Literature

25 PT-NANB viruses and antigens have been reported. See for example, U.S. Patent Nos. 4,464,474, and 4,542,016. The PT-NANB virus has been reported to be a togavirus. See, for example, U.S. Patent No. 4,464,474. Genetic engineering of hepatitis viral
30 genes, identified as hepatitis C virus, is reported in European Patent Application 88310922.5 (publication number 0 318 216 A1).

SUMMARY OF THE INVENTION

35

In accordance with the subject invention, isolates comprising virus particles associated with PT-

NANB hepatitis and genomic material derived therefrom, together with methods for their preparation and use, are provided. The virus particles are characterized as being obtainable from cells susceptible to NANB hepatitis infection in a host infected with NANB hepatitis; capable of inducing NANB hepatitis in a susceptible host; and capable of inducing expression of NANB virus specific antigens in cells susceptible to infection by the virus. The virus particles can be used as a source of genomic material for preparing polynucleotide probes for diagnosis, as well as antigens and vaccines for therapeutic and diagnostic applications. Propagation of the virus particles in vitro can be used to identify virus-specific cell-surface antigens, and as a source of such antigens. Attenuated or inactivated virus particles can be used as vaccines.

BRIEF DESCRIPTION OF THE DRAWINGS

20

Figure 1 shows a fragment of PT-NANB virus derived from clone #30. The top line represents the amino acid sequence which is encoded by the nucleotide sequence shown in the lower line.

25

Figure 2 shows a fragment of PT-NANB virus derived from λ gt-11 clone PT-2. Abbreviations are as for Figure 1.

30

Figure 3 shows a fragment of PT-NANB virus derived from λ gt-11 clone PT-8. Abbreviations are as for Figure 1.

Figure 4 shows a fragment of PT-NANB virus derived from λ gt-11 clone PT-19. Abbreviations are as for Figure 1.

35

Figure 5 shows a series of 7 fragments of PT-NANB virus genetic material. Only the cDNA sequences are shown in this Figure.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The present invention provides unambiguously identified viral genetic material and a source of virus particles associated with post transfusion non-A, non-B (NANB) hepatitis. The virus particles may be obtained from samples suspected of containing virus particles, such as serum of infected humans and other anthropoid species, by fractionation of the samples based upon buoyant density and from cells susceptible to infection with NANB virus, such as hepatocytes. The virus particle isolates may be used directly as a source of genomic material for preparing probes for diagnosis, antigens and vaccines for therapeutic and diagnostic purposes, or they may be propagated in a susceptible cell line such as a trioma comprising human hepatocytes. The infected cells may be used either as a source of virus particles or may be used for identifying NANB virus specific antibodies or antigens, and as a source of such antigens.

Viral particles can be obtained from an infected human or other infected source such as a chimpanzee, from plasma, or from other cells susceptible to infection by NANB virus, such as the hepatocyte. To obtain viral genomic material, the biological sample can be centrifuged and viral RNA extracted from viral particles in the sample. Alternatively, a purified fraction comprising viral particles may be obtained by fractionation of the sample on a density gradient, such as a sucrose density gradient. Fractions having a buoyant density of from about 1.07 to about 1.13 gm/cm³, preferably 1.09 to 1.11 gm/cm³ are collected. Fractions comprising the virus particles can then be extracted and cDNA clones prepared from the viral RNA. The virus may be further characterized as having a genome comprising RNA sequences which may be reverse transcribed to obtain at

least one of the cDNA sequences shown in Figures 1-5. All of these sequences are derived from viral genetic material isolated from humans or chimpanzees infected with PT NANB. For example, the first five sequences
5 shown in Figure 5 are derived from virus obtained from humans. These sequences are derived from different segments of the viral genome and appear to be unrelated. The last two sequences shown in Figure 5 are derived from virus obtained from infected
10 chimpanzees. All of these sequences appear to be different from previously known NANB sequences, such as those disclosed in published European application
0 318 216 A1, which was mentioned above as identifying hepatitis C viral segments.

15 Any sequence of nucleotides from the above sequences may be used as a probe or primer for detecting or regulating the viral nucleic acid. Such probes can be considerably shorter than the entire sequence but should be at least 16 nucleotides in
20 length. Intermediate oligonucleotides from 20 to 500, especially 30 to 200, nucleotides in length provide particularly specific and rapid-acting probes. Longer oligonucleotides are also useful, up to the full length of a gene. Both RNA and DNA probes may be used. In
25 addition, an at least 8, usually at least 12 amino acid sequence, conveniently at least a 20-amino acid sequence, may be employed as an epitopic site, an immunodominant sequence, a hapten or the like for the production of diagnostic reagents, vaccines, production
30 of antibodies, isolation of antibodies from serum or the like. Usually, the isolated peptide will be fewer than about 125 amino acids, frequently fewer than about 100 amino acids. Amphipathic sequences or sequences fulfilling the Rothbard algorithm may be used, as
35 exemplified by G-V-V-Y-D-N-D-D, or E-P-V-N-P-K-D-P.

Sequences homologous with the viral sequences should hybridize and be detectable under the conditions

described for detecting/hybridizing RNA in Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982, p. 332. See also, pages 324-328 for DNA hybridization conditions, particularly paragraph 6, p. 325.

Since significant sequences of genetic material (as cDNA) have been fully identified, it is possible to produce a variety of DNA and RNA sequences based on this natural sequence partially or entirely by synthetic chemistry, after which the sequences obtained can be inserted into any of the many available DNA vectors using known techniques of recombinant DNA technology. Thus the present invention can be carried out using reagents, plasmids, and microorganism which are freely available and in the public domain at the time of filing of this patent application.

For example, nucleotide sequences greater than 100 nucleotides in length can be readily synthesized on an Applied Biosystems Model 380A DNA Synthesizer as evidenced by commercial advertising of the same (e.g., Genetic Engineering News, November/December 1984, p. 3). Such oligonucleotides can readily be spliced using, among others, the technique of preparing overlapping complementary sequences (e.g., 1-100 of coding strand, 0-50 and 51-150 of complementary strand, 101-200 of coding strand, etc.) followed by hybridizing and ligating the strands.

Furthermore, automated equipment is also available that makes direct synthesis of any of the peptides disclosed herein readily available. In the same issue of Genetic Engineering News mentioned above, a commercially available automated peptide synthesizer having a coupling efficiency exceeding 99% is advertised (page 34). Such equipment provides ready access to the peptides of the invention, either by direct synthesis or by synthesis of a series of fragments that can be coupled using other known techniques.

In addition to the specific polypeptide sequences shown in Figures 1 to 5, peptide fragments based on these sequences and fragments representing minor variations thereof will have the biological activity of the various peptides. For example, fragments of the given peptide sequence that are capable of being recognized by immunoglobulins specific for NANB hepatitis can readily be prepared and screened. Peptide synthesizers can be used to prepare small polypeptide fragments (e.g., less than 100 amino acids) or techniques of genetic engineering can be used to prepare larger fragments. A simple screening procedure that will identify suitable polypeptide fragments consists of preparing monoclonal antibodies to an entire encoded antigen, attaching the antibodies to an affinity column, and capturing peptide fragments that are retained by the bound antibody. Polyclonal antisera can be used instead of monoclonal antibodies if desired. The suitability of this technique has been demonstrated experimentally.

The ability to prepare and select appropriate immunologically active fragments from a larger protein is well known in the art and is described in a number of publications, including patents. See, for example, U.S. Patent No. 4,629,783, which describes the preparation of immunologically active fragments of viral proteins. One common variation is the preparation of a polypeptide of the invention in the form of a fused polypeptide. Such peptides are typically prepared by using the promoter region of a gene known to be expressed in a host and inserting nucleotides that encode all or a major portion of the amino acid sequence of the invention into the genetic sequence for the host protein. Examples of such fused proteins include the β -galactosidase fused protein discussed below.

Another technique for preparing immunologically active peptide fragments is to synthesize a series

of amino acids of from 5-100 amino acids in length (or any intervening length, such as 10, 15, or any other multiple of 2, 3, or 5 in this range) and screen for immunological activity using an antiserum (or mono-
5 clonal antibody). The fragments are selected along the entire length of the peptide to optimize cross-reactivity (e.g., a series of peptides 20 amino acids in length and comprising AA₁-AA₂₀, AA₅-AA₂₅, AA₁₀-AA₃₀, etc.). The selected fragment then corresponds to
10 particularly useful corresponding nucleotide sequences that can be used to produce large amounts of the peptide by recombinant techniques, for use as described herein.

In addition, minor variations of the previously
15 ly mentioned peptides and DNA molecules are also contemplated as being equivalent to those peptides and DNA molecules that are set forth in more detail, as will be appreciated by those skilled in the art. For example, it is reasonable to expect that an isolated replacement
20 of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, a cysteine with a serine or alanine, or a similar replacement of an amino acid with a structurally related amino acid (i.e., a conservative replacement) will not have a
25 major effect on the biological activity of the resulting molecule, especially if the replacement does not involve an amino acid at a binding site or other site of biologic activity. Whether a change results in a functioning peptide can readily be determined by direct
30 analysis for function in an immunization or in a diagnostic test that relies on immunogenic specificity. Examples of this process are described later in detail. Peptides in which more than one replacement has taken place can readily be tested in the same
35 manner. Preferred peptides differ at no more than 12, more preferably no more than 5, amino acids in any contiguous group of 20 amino acids. Standard conser-

vative groups of amino acids are shown in parenthesis using the one-letter amino acid code: nonpolar (A,V,L,I,P,M); aromatic (F,T,W); uncharged polar (G,S,T,C,N,Q); acidic (D,E); basic (K,R,H). The aromatic groups are sometimes considered to belong to the broader-defined nonpolar (F,W) or uncharged polar (T) groups.

Other DNA molecules that code for such peptides can readily be determined from the list of codons in Table 1 and are likewise contemplated as being equivalent to the DNA sequences of Figures 1 to 5. Since there is a fixed relationship between DNA codons and amino acids in a peptide, any discussion in this application of a replacement or other change in a peptide is equally applicable to the corresponding DNA sequence or to the DNA molecule, recombinant vector, or transformed microorganism in which the sequence is located (and vice versa).

20

25

30

35

TABLE 1
The Genetic Code¹

| | First Position (5' end) | Second Position | | | | Third Position (3' end) |
|----|-------------------------------|--------------------|-----|------|------|-------------------------------|
| | | U | C | A | G | |
| 10 | U | PHE | SER | TYR | CYS | U |
| | | PHE | SER | TYR | CYS | C |
| | | LEU | SER | Stop | Stop | A |
| | | LEU | SER | Stop | TRP | G |
| 15 | C | LEU | PRO | HIS | ARG | U |
| | | LEU | PRO | HIS | ARG | C |
| | | LEU | PRO | GLN | ARG | A |
| | | LEU | PRO | GLN | ARG | G |
| 20 | A | ILE | THR | ASN | SER | U |
| | | ILE | THR | ASN | SER | C |
| | | ILE | THR | LYS | ARG | A |
| | | MET | THR | LYS | ARG | G |
| 25 | G | VAL | ALA | ASP | GLY | U |
| | | VAL | ALA | ASP | GLY | C |
| | | VAL | ALA | GLU | GLY | A |
| | | VAL | ALA | GLU | GLY | G |

¹ Given the position of the bases in a codon, it is possible to find the corresponding amino acid. For example, the codon (5')AUG(3') on mRNA specifies methionine, whereas CAU specifies histidine. UUA, UAG, and UGA are termination signals. AUG is part of the initiation signal, and it codes for internal methionines as well.

In addition to the specific nucleotide sequences listed in Figures 1 to 5, DNA (or corresponding RNA) molecules of the invention can have additional nucleotides preceding or following those that are specifically listed. For example, poly A can be added to the 3'-terminus of the cDNA, a short (e.g., fewer than 20 nucleotides) sequence can be added to either terminus to provide a terminal sequence corresponding to a restriction endonuclease site, stop codons can follow the peptide sequence to terminate translation, and the like. Additionally, DNA molecules containing a promoter region or other control region upstream from the gene can be prepared. All DNA molecules containing the sequences of the invention will be useful for at least one purpose since all can minimally be fragmented to produce oligonucleotide probes and be used in the isolation or detection of PT NANB specific nucleic acid sequences from biological sources.

Peptides of the invention can be prepared for the first time as homogeneous preparations, either by direct synthesis or by using a cloned gene or a fragment thereof as described herein. By "homogeneous" is meant, when referring to a peptide or DNA sequence, that the primary molecular structure (i.e., the sequence of amino acids or nucleotides) of substantially all molecules present in the composition under consideration is identical. The term "substantially" as used in the preceding sentence preferably means at least 95% by weight, more preferably at least 99% by weight, and most preferably at least 99.8% by weight. The presence of fragments derived from entire molecules of the homogeneous peptide or DNA sequence, if present in no more than 5% by weight, preferably 1% by weight, and more preferably 0.2% by weight, is not to be considered in determining homogeneity since the term "homogeneous" relates to the presence of entire molecules (and fragments thereof) that have a single defined

structure as opposed to mixtures in which several molecules of similar molecular weight are present but which differ in their primary molecular structure.

The term "isolated" as used herein refers to
5 pure peptide, DNA, or RNA separated from other peptides, DNAs, or RNAs, respectively, and being found in the presence of (if anything) only a solvent, buffer, ion or other component normally present in a biochemical solution of the same. "Isolated" does not encompass
10 either natural materials in their native state or natural materials that have been separated into components (e.g., in an acrylamide gel) but which have not been obtained either as pure substances or as solutions. The term "pure" as used herein preferably has
15 the same numerical limits as "substantially" immediately above. The phrase "replaced by" or "replacement" as used herein does not necessarily refer to any action that must take place but to the peptide that exists when an indicated "replacement" amino acid is present
20 in the same position as the amino acid indicated to be present in a different formula.

Salts of any of the biological molecules described herein will naturally occur when such molecules are present in (or isolated from) aqueous solutions of
25 various pHs. All salts of molecules having the indicated biological activity are considered to be within the scope of the present invention. Examples of salts that can occur with peptides include alkali, alkaline earth, and other metal salts of carboxylic acid residues, acid
30 addition salts (e.g., HCl) of amino residues, and zwitterions formed by reactions between carboxylic acid and amino residues within the same molecule.

The invention specifically contemplates each and every possible variation of polynucleotide that
35 could be made by selecting combinations based on the possible codon choices listed in Figures 1 to 5 and Table 1, and all such variations are to be considered

as having been specifically disclosed. In order to avoid redundancy, such variations are not set forth here.

Although genes and corresponding proteins can
5 be prepared by the totally synthetic techniques discussed above, in preferred embodiments of the invention genetic information is obtained from natural sources and identified as described herein. The genetic material is first obtained in the form of a gene library,
10 using any of numerous existing techniques. The first of these is to randomly shear genomic DNA and insert this sheared material into expression vectors, e.g., λ gt11. If enough recombinants are generated, there is a good probability of having at least one
15 recombinant in the population which is expressing a fusion protein corresponding to an antigen of interest. In practice, for a genome the size of the present virus (about 10 kbp, as DNA) at least about 6×10^3 independent recombinants are needed. This allows for the
20 entire genome to be represented by recombinants with an average insert size of 100 bp where at least one insert will exist with one of its ends falling within any 10-base-pair region. Allowing for only 1 in 6 such insertions being in the correct orientation and reading
25 frame, functional recombinants should exist in such a library with fusions corresponding to approximately every 10 base pairs.

A second strategy for preparing gene libraries is to make complementary DNA (cDNA) copies of the total
30 RNA of the virus and to clone these as recombinant molecules in expression vectors. Use of a cDNA library to obtain genetic information for use in the present invention is preferred. Such a library has been generated from NANB-infected human plasma and screened
35 with serum from a NANB-infected human. Among the recombinants expressing determinants reactive with the serum are those described in Figures 1 to 4.

Polyclonal antisera to NANB can be used to screen a cDNA library in order to locate the desired genetic material. cDNA fragments are inserted into an expression vector and after transformation into a suitable host, the host may be screened for proteins which bind to the polyclonal antisera. Recombinants initially identified in this manner can be isolated. The resulting clones may then be used as probes to further search the library for larger fragments or partially overlapping fragments until the complete cDNA is identified.

The NANB genetic material can be used for the production of full fragments or of modified peptides using standard techniques of manipulating and growing unicellular microorganisms. Antigens which are candidates for vaccine development and/or diagnostic reagents will include those recognized by serum from infected patients. Additionally, any of the genetic sequences can be used as probes in hybridization assays.

Although the techniques set forth above, when used in combination with the knowledge of those skilled in the art of genetic engineering and the previously stated guidelines, will enable isolation of the desired genetic material and its use in recombinant DNA vectors in conjunction with the disclosed sequence, other methods which lead to the same result are also known and may be used in the preparation of recombinant DNA vectors of this invention.

Expression of protein, e.g., for use in vaccines, can be enhanced by including multiple copies of the gene in a transformed host, by selecting a vector known to reproduce in the host (such as pUC8; ptacl2; pIN-III-ompA1, 2, or 3; pOTS; pAS1; or pKK223-3), thereby producing large quantities of protein from exogenous inserted DNA or by any other known means of enhancing peptide expression. In all cases, a viral

protein will be expressed when the DNA sequence is functionally inserted into the vector. By "functionally inserted" is meant in proper reading frame and orientation, as is well understood by those skilled in the art. Typically, a gene will be inserted downstream from a promoter and will be followed by a stop codon, although production as a hybrid protein (possibly followed by cleavage) may be used, if desired.

In addition to the above, general procedures which can be used for preparing recombinant DNA molecules and transformed unicellular organisms in accordance with the practices of this invention, other known techniques and modifications thereof can be used in carrying out the practice of the invention. In particular, techniques relating to genetic engineering have recently undergone explosive growth and development. Many recent U.S. patents disclose plasmids, genetically engineered microorganisms, and methods of conducting genetic engineering which can be used in the practice of the present invention. For example, U.S. Patent No. 4,273,875 discloses a plasmid and a process of isolating the same. U.S. Patent No. 4,304,863 discloses a process for producing bacteria by genetic engineering in which a hybrid plasmid is constructed and used to transform a bacterial host. U.S. Patent No. 4,419,450 discloses a plasmid useful as a cloning vehicle in recombinant DNA work. U.S. Patent No. 4,362,867 discloses recombinant cDNA construction methods and hybrid nucleotides produced thereby which are useful in cloning processes. U.S. Patent No. 4,403,036 discloses genetic reagents for generating plasmids containing multiple copies of DNA segments. U.S. Patent No. 4,363,877 discloses recombinant DNA transfer vectors. U.S. Patent No. 4,356,270 discloses a recombinant DNA cloning vehicle and is a particularly useful disclosure for those with limited experience in the area of genetic engineering since it defines many of the terms used

in genetic engineering and the basic processes used therein. U.S. Patent No. 4,336,336 discloses a fused gene and a method of making the same. U.S. Patent No. 4,349,629 discloses plasmid vectors and the production and use thereof. U.S. Patent No. 4,332,901 discloses a cloning vector useful in recombinant DNA. Although some of these patents are directed to the production of a particular gene product that is not within the scope of the present invention, the procedures described therein can easily be modified to the practice of the invention described in this specification by those skilled in the art of genetic engineering by substitution of a subject sequence for the existing open reading frame sequence.

The implications of the present invention are significant in that unlimited supplies of NANB viral proteins and genetic material of the subject strain will become available for use in the development of hybridization assays or in any other type of assay utilizing these materials as a reagent for use in diagnosis, immunization, therapeutics, and research. Methods of using genetic material in a hybridization assay and equipment for expansion and amplification of genetic material are commercially available in the PCR system (Perkin-Elmer Cetus).

Particularly contemplated is the isolation of genes and viral genomes that can express protein from the subject virus using oligonucleotide probes based on the principal and variant nucleotide sequences disclosed herein. In use, the probes are typically labeled in a detectable manner (e.g., with a radio-nuclide, e.g., ^{32}P , ^3H , or with biotin) and are incubated with single-stranded DNA or RNA from the organism in which a sequence is being sought. Hybridization is detected by means of the label after single-stranded and double-stranded (hybridized) DNA (or DNA/RNA) have been separated (typically using

nitrocellulose paper). Hybridization techniques suitable for use with oligonucleotides are well known. Identity of virus or genetic material obtained from any source with the virus and genetic material of the invention can be confirmed by hybridization assays using probes prepared from the genetic sequences described herein.

Although probes are normally used with a detectable label that allows easy identification, unlabeled oligonucleotides are also useful, both as precursors of labeled probes and for use in methods that provide for direct detection of double-stranded DNA (or DNA/RNA), such as absorption onto nitrocellulose. Accordingly, the term "oligonucleotide probe" refers to both labeled and unlabeled forms.

Additionally, it is possible to purify virus particles from any source and reduce the amount of screening necessary for identifying virus particles and genetic material associated with NANB hepatitis by fractionating, according to buoyant density, biological samples suspected of containing virus, such as a viral pellet obtained from serum or other bodily fluid of an anthropoid infected with NANB hepatitis. By selecting fractions of the proper buoyant density, samples are enriched for the specific virus of the invention. Virtually 100% of a titered inoculum may be recovered from the buoyant density fractions described herein.

Using such techniques, clones have been prepared and characterized as making an immuno-reactive protein recognized by NANB antiserum (a β -gal fusion product). The genetic material is exogenous to both human and chimpanzee genomes (both infected and uninfected) and, after amplification of the genetic material extracted from buoyant density fractionated serum, is positive for hybridization with a sample obtained from an NANB-infected chimpanzee and negative in the same analysis when tested against amplified

genetic material obtained from a control chimpanzee infected with hepatitis B virus.

As a means of propagating relatively large amounts of viral genomic material, viruses of the invention can be cultured in vitro using a hybrid cell line susceptible to infection by the virus. Immortalized virus-specific tissue cells which can be used to culture the NANB viruses of the invention are specifically described in U.S. Application Serial No. 846,757, filed April 1, 1986. Techniques for obtaining virus particles from cell culture are described in the above-identified application and in U.S. Patent No. 4,464,474 which disclosure is hereby incorporated by reference.

The general methods for infecting and culturing the hybrid cells with a selected human infectious virus are as follows: Plasma from a human or other NANB-infected source such as a chimpanzee is used to infect the hybrid cells, and viral infection is followed by monitoring a virus-related cell change over time in culture. NANB virus infection is characterized by the appearance of virus-specific antigens, so the viral infection is properly followed by immunological methods for detecting antigens. After viral infection and propagation, the virus can be isolated, if desired, by conventional means for releasing and purifying virus particles from cells. For example, virus particles may be isolated by lysing the cells and subjecting the lysate to the technique of fractionating samples according to buoyant density, as described below, without additional purification techniques that might disrupt virus particles. The isolated particles will reproduce the virus-related cell change when uninfected hybrid cells are exposed to virus particles.

It may be desirable for a variety of reasons to further purify the particles present in a sample containing particles of the invention. For example, if a virus particle is to be treated and employed as a

vaccine or in an immunoassay, there ordinarily should be as little in the way of extraneous protein contamination as possible. Thus, the particle should be substantially free of primate proteins.

5 NANB viral antigens may be obtained from a variety of sources. The antigen may be present on an intact virus particle, a partially degraded virus particle, a protein- or carbohydrate-containing molecule in solution, or any other physical form,
10 including an antigen that has been combined either chemically or physically with particle or solid surfaces, such as by attaching antigens to the surface of a test tube or to suspended particles, such as red blood cells or latex particles. An antigen of the
15 invention is defined as a substance containing at least one epitopic site of a virus particle.

To obtain NANB viral antigens, the antigens, whether soluble or in some other form, are typically first separated from water insoluble contaminants
20 having greater dimensions or different density than the intact particles, such as animal cells and cell debris and cellular microorganisms, such as bacteria. This gross separation is generally accomplished by low-speed centrifugation or by filtration using standard
25 techniques. Ordinary filters having an average pore diameter of 0.45 microns are useful in retaining gross contamination and passing through the antigens.

Additionally, antigens of the invention may be separated from undesired water-soluble materials after
30 gross contamination is removed. Where it is desired to recover either intact virus particles or their water-insoluble fragments, it is convenient to simply remove all water soluble constituents from the sample. Suitable techniques include ultrafiltration through a
35 membrane, use of selective flocculating or protein-precipitating agents (such as polyethylene glycol and ammonium sulfate), and chromatography. Chromatography

is the most versatile method since it can be readily scaled up for commercial manufacture of antigen. Gel chromatography systems using cross-linked dextran beads are typical of the materials used. A column of a suitable gel can be selected which will permit diffusion of proteins and low molecular weight substances into the void volume of the gel beads, thereby retarding the progress of these contaminants through the column, while allowing whole virus particles to pass through virtually unimpeded. When a particular antigen is desired, other gel sizes can be selected to provide for isolation of an antigen of any particular size. The gel which is selected will thus be a matter of routine experimentation.

Any of the techniques described herein can be combined as desired. For example, isolation of particles on a cesium chloride or sucrose density gradient can be followed by disruption of particles using any of a variety of techniques and isolation of a viral antigen on gel electrophoresis, selecting for proteins binding to antibodies, e.g., antisera, specific for NANB antigens.

One technique that is particularly suitable for isolating soluble protein antigens or particle fragments is affinity chromatography. Antibodies capable of binding antigens of the invention are covalently linked or adsorbed to an insoluble support using conventional procedures. The coupled antibody is placed in a column. A sample containing antigen is passed through the column, where it binds to the coupled antibody. The immunologically-bound antigen is washed with buffer and can then be released by, for example, changing the ionic strength or pH of the wash buffer. Generally, an acidic pH is effective for releasing the bound antigen. The technique is highly effective in separating closely related proteins from the antigens of the invention.

Antigens of the invention can be used as a vaccine. A preferred starting material for preparation of a vaccine is the particle antigens produced by tissue culture of the infectious virus. The antigens are preferably initially recovered as intact particles as described above. However, it is also possible to prepare a suitable vaccine from particles isolated from other sources or non-particle recombinant antigens. When non-particle antigens are used (typically soluble antigens), proteins native to the viral envelope or viral capsid are preferred for use in preparing vaccines. These proteins can be purified by affinity chromatography, also described above.

If the purified protein is not immunogenic per se, it can be bound to a carrier to make the protein immunogenic. Carriers include bovine serum albumin, keyhole limpet hemocyanin and the like. It is desirable, but not necessary to purify antigens to be substantially free of human protein. However, it is more important that the antigens be free of proteins, viruses, and other substances not of human origin that may have been introduced by way of, or contamination of, the nutrient medium, cell lines, tissues, or pathological fluids from which the virus is cultured or obtained.

Vaccination can be conducted in conventional fashion. For example, the antigen, whether a viral particle or a protein, can be used in a suitable diluent such as water, saline, buffered salines, complete or incomplete adjuvants, and the like. The immunogen is administered using standard techniques for antibody induction, such as by subcutaneous administration of physiologically compatible, sterile solutions containing inactivated or attenuated virus particles or antigens. An immune response producing amount of virus particles is typically administered per vaccinating injection, typically in a volume of one milliliter or less.

In addition to use as a vaccine, the compositions can be used to prepare antibodies to NANB virus particles. The antibodies can be used directly as antiviral agents. To prepare antibodies, a host animal
5 is immunized using the virus particles or, as appropriate, non-particle antigens native to the virus particle are bound to a carrier as described above for vaccines. The host serum or plasma is collected following an appropriate time interval to provide a
10 composition comprising antibodies reactive with the virus particle. The gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art. The
15 antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs.

The antibody compositions can be made even more compatible with the host system by minimizing
20 potential adverse immune system responses. This is accomplished by removing all or a portion of the Fc portion of a foreign species antibody or using an antibody of the same species as the host animal, for example, the use of antibodies from human/human
25 hybridomas (see below).

The antibodies can also be used as a means of enhancing the immune response since antibody-virus complexes are recognized by macrophages. The antibodies can be administered in amounts similar to those
30 used for other therapeutic administrations of antibody. For example, pooled gamma globulin is administered at 0.02-0.1 ml/lb body weight during the early incubation of other viral diseases such as rabies, measles and hepatitis B to interfere with viral entry
35 into cells. Thus, antibodies reactive with the NANB virus particle can be passively administered alone or in conjunction with another anti-viral agent to a host

infected with a NANB virus to enhance the immune response and/or the effectiveness of an antiviral drug.

Alternatively, anti-NANB-virus antibodies can be induced by administering anti-idiotypic antibodies as immunogens. Conveniently, a purified anti-NANB-virus antibody preparation prepared as described above is used to induce anti-idiotypic antibody in a host animal. The composition is administered to the host animal in a suitable diluent. Following administration, usually repeated administration, the host produces anti-idiotypic antibody. To eliminate an immunogenic response to the Fc region, antibodies produced by the same species as the host animal can be used or the Fc region of the administered antibodies can be removed. Following induction of anti-idiotypic antibody in the host animal, serum or plasma is removed to provide an antibody composition. The composition can be purified as described above for anti-NANB-virus antibodies, or by affinity chromatography using anti-NANB-virus antibodies bound to the affinity matrix. The anti-idiotypic antibodies produced are similar in conformation to the authentic NANB antigen and may be used to prepare a NANB vaccine rather than using a NANB particle antigen.

When used as a means of inducing anti-NANB-virus antibodies in a patient, the manner of injecting the antibody is the same as for vaccination purposes, namely intramuscularly, intraperitoneally, subcutaneously or the like in an effective concentration in a physiologically suitable diluent with or without adjuvant. One or more booster injections may be desirable. The anti-idiotypic method of induction of anti-NANB-virus antibodies can alleviate problems which may be caused by passive administration of anti-NANB-virus antibodies, such as an adverse immune response, and those associated with administration of purified blood components, such as infection with other as yet

uncharacterized agents.

In addition to therapeutic uses, the particles and antigens of the invention, as well as the genetic material, can be used in diagnostic assays. Methods for
5 detecting the presence of NANB hepatitis comprise analyzing a biological sample such as a blood sample or liver biopsy specimen for the presence of an analyte associated with NANB hepatitis virus. The analyte can be a nucleotide sequence which hybridizes with a probe
10 comprising a sequence of at least about 16 consecutive nucleotides, usually 30 to 200 nucleotides, up to substantially the full sequence of the cDNA sequence shown in Figures 1 to 5. The analyte can be RNA or cDNA.

15 The analyte can be a virus particle having at least one of the following characteristics: obtainable from cells susceptible to infection with NANB hepatitis; capable of inducing expression of virus-specific surface antigen in a cell susceptible to infection by
20 the particle, the surface antigen being recognized by serum from a host infected with NANB and not by serum from a non-infected host; having a buoyant density of from about 1.09 to 1.11 gm/cm². The virus particle can be further characterized as having an RNA viral genome
25 comprising a sequence at least about 80% homologous to a sequence of at least 12 consecutive nucleotides of the sequences in Figures 1 to 5, usually at least about 90% homologous to at least about 60 consecutive nucleotides within the sequence, and may comprise a sequence
30 substantially homologous to the sequences in Figures 1 to 5. The analyte can comprise an antibody which recognizes an antigen, such as a cell surface antigen, on a NANB virus particle. The analyte can also be a NANB viral antigen.

35 In order to detect an analyte, where the analyte hybridizes to a probe the probe may contain a detectable label. Likewise, where the analyte is an

antibody or an antigen, either a labelled antigen or antibody, respectively, can be used to bind to the analyte to form an immunological complex, which can then be detected by means of the label.

5 Typically, methods for detecting analytes such as surface antigens and/or whole particles are based on immunoassays. Immunoassays can be conducted either to determine the presence of antibodies in the host that have arisen from infection by NANB hepatitis virus or
10 by assays that directly determine the presence of virus particles or antigens. Such techniques are well known and need not be described here in detail. Examples include both heterogeneous and homogeneous immunoassay techniques. Both techniques are based on the formation
15 of an immunological complex between the virus particle or its antigen and a corresponding specific antibody. Heterogeneous assays for viral antigens typically use a specific monoclonal or polyclonal antibody bound to a solid surface. Sandwich assays are becoming increas-
20 ingly popular. Homogeneous assays, which are carried out in solution without the presence of a solid phase, can also be used, for example by determining the difference in enzyme activity brought on by binding of free antibody to an enzyme-antigen conjugate. A number
25 of suitable assays are disclosed in U.S. Patent Nos. 3,817,837, 4,006,360, 3,996,345.

When assaying for the presence of antibodies induced by NANB viruses, the viruses and antigens of the invention can be used as specific binding agents to
30 detect either IgG or IgM antibodies. Since IgM antibodies are typically the first antibodies that appear during the course of an infection, when IgG synthesis may not yet have been initiated, specifically distinguishing between IgM and IgG antibodies present in the
35 blood stream of a host will enable a physician or other

investigator to determine whether the infection is recent or chronic.

The genetic material of the invention can itself be used in numerous assays as probes for genetic material present in naturally occurring infections. One method for amplification of target nucleic acids, for later analysis by hybridization assays, is known as the polymerase chain reaction or PCR technique. The PCR technique can be applied to detecting virus particles of the invention in suspected pathological samples using oligonucleotide primers spaced apart from each other and based on the genetic sequence set forth in Figures 1 to 5. The primers are complementary to opposite strands of a double stranded DNA molecule and are typically separated by from about 50 to 450 nt or more. This method entails preparing the specific oligonucleotide primers and then repeated cycles of target DNA denaturation, primer binding, and extension with a DNA polymerase to obtain probes of the desired length. Extension products generated from one primer serve as additional target sequences for the other primer. The degree of amplification of a target sequence is controlled by the number of cycles that are performed and is theoretically calculated by the simple formula 2^n where n is the number of cycles. Given that the average efficiency per cycle ranges from about 65% to 85%, 25 cycles produce from 0.3 to 4.8 million copies of the target sequence. The PCR method is described in a number of publications, including Saiki *et al.*, Science (1985) 230:1350-1354; Saiki *et al.*, Nature (1986) 324:163-166; and Scharf *et al.*, Science (1986) 233:1076-1078. Also see U.S. Patent Nos. 4,683,194; 4,683,195; and 4,683,202.

For both *in vivo* use of antibodies to NANB-virus particles and proteins and anti-idiotypic antibodies and diagnostic use, it may be preferable to use monoclonal antibodies. Monoclonal anti-virus particle

antibodies or anti-idiotypic antibodies can be produced as follows. The spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art. To produce a human-human hybridoma, a human lymphocyte donor is selected. A donor known to be infected with a NANB virus (where infection has been shown for example by the presence of anti-virus antibodies in the blood or by virus culture) may serve as a suitable lymphocyte donor. Lymphocytes can be isolated from a peripheral blood sample or spleen cells may be used if the donor is subject to splenectomy. Epstein-Barr virus (EBV) can be used to immortalize human lymphocytes or a human fusion partner can be used to produce human-human hybridomas. Primary in vitro immunization with peptides can also be used in the generation of human monoclonal antibodies.

Antibodies secreted by the immortalized cells are screened to determine the clones that secrete antibodies of the desired specificity. For monoclonal anti-virus particle antibodies, the antibodies must bind to NANB virus particles. For monoclonal anti-idiotypic antibodies, the antibodies must bind to anti-virus particle antibodies. Cells producing antibodies of the desired specificity are selected.

The invention now being generally described, the same will be better understood by reference to the following examples which are provided for purposes of illustration only and are not to be considered limiting of the invention unless so specified.

EXPERIMENTAL

Two hybrid liver cell cultures infected with NANB virus particles were deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20882, on June 24, 1988. The two

hybrid cultures are GLH03 and GLH04, and were given ATCC accession numbers CRL 9754 and CRL 9755, respectively. An uninfected hybrid liver-cell culture GLH02 was deposited with the ATCC on March 26, 1986 and given
5 ATCC accession number HB 9027.

Example 1

Preparation of cDNA Clone from NANB

Particles Isolated from Human Serum

10 Serum from human patients diagnosed as having NANB hepatitis was centrifuged at 30,000 rpm for 2-1/2 hrs at 5°C in an SW40 rotor (Beckman). The supernatant was removed and discarded and the pellet solubilized in 50 mM sodium acetate buffer, pH 4.8, containing 1%
15 sodium dodecylsulfate (SDS). The RNA was selectively extracted using phenol equilibrated in the same buffer without SDS. The nucleic acid in the aqueous phase was then precipitated using two volumes of absolute ethanol. The RNA was reverse-transcribed into double-
20 stranded cDNA using a DNA synthesis kit following the procedure specified by the manufacturer (Boehringer-Mannheim Biochemicals, Indianapolis, Indiana) except for the substitution of random primers for the oligo dt primer provided in the kit. The dsDNA obtained was
25 ligated to EcoRI linkers and after generation of the cohesive EcoRI sites, was inserted into λ gt11 as described by the supplier (ProMega Biotech, Madison, Wisconsin). The plaques were screened with NANB-infected human antisera and positive clones were
30 isolated. The clones were then rescreened using the NANB-infected human antisera and plaque-purified.

Analysis of the sequences shown in Figures 1 to 4 using available sequence homology search programs revealed that the cloned sequences were unlike any
35 entered in the data bank (GenBank versions 54 and 57). No homology was found to polypeptide sequences contained in GenBank version 52. Analysis of the DNA

sequences shown in Figure 5 (against GenBank version 57) showed no significant homology.

Example 2

5 Purification of NANB Virus Particles From Infected Chimpanzee Plasma

NANB virus particles originally derived from human plasma were isolated as follows: A plasma inoculum from a chimpanzee inoculated with infected
10 plasma comprising NANB virus particles originating from a patient diagnosed as having NANB hepatitis but carried in chimpanzees was layered onto the top of a linear 20-55% sucrose gradient in Tris HCl 0.01 M, pH 8.0, containing 0.001 M EDTA, 0.1 M sodium chloride.
15 The gradient was prepared using a Hoefer gradient maker. The chimpanzee inoculum contained 10^6 chimpanzee infectious doses (CID) of NANB virus particles. The gradient was centrifuged for 18 hrs at 30,000 rpm at 5°C in an SW40 rotor. Following fractionation of
20 the gradient, the fractions were analyzed for infectivity by reinjection into chimpanzees. Fractions having a buoyant density of 1.09 to 1.11 gm/cm³ were infectious at a dilution of 1:10⁶, based upon alanine amino transferase (ALT) elevation at about 30 days post-
25 inoculation into the chimpanzee.

Example 3

Preparation of cDNA from Purified Virus Particles

The virus particles obtained as described in
30 Example 2, having a buoyant density of from 1.09 to 1.11 gm/cm³ were used to prepare cDNA as described in Example 1. The cDNA obtained was then amplified using a technique described in co-owned patent Application Serial No. 208,512, filed June 17, 1988, which
35 disclosure is incorporated herein by reference. As a control, amplified cDNA was prepared from the buoyant density fractionated plasma of a chimpanzee chronically

infected with HBV in the same manner as for the NANB cDNA. Infected and control amplified cDNAs were electrophoresized using an agarose gel (2%) and then transferred to nitrocellulose filters by the method of Southern (J. Mol. Biol. (1975) 98:503).

Clone #30 (obtained as in Example 1; sequence as in Figure 1) was radiolabeled using ^{32}P nucleotides and a random primer kit according to the instructions provided by the kit manufacturer (Boehringer-Mannheim Biochemicals, Indianapolis, Indiana). The radio-labeled clone #30 was then used as a hybridization probe against a filter containing the amplified cDNAs from the fractionated virus particles. Specific hybridization, as detected by autoradiography, was evident only with the cDNA prepared from the NANB-infected chimpanzee. It was thus demonstrated that the molecular clone #30 isolated from a NANB-infected human source (identified by using serum from a different NANB-infected human and characterized as exogenous to the human and chimpanzee genomes) detected homologous sequences present in cDNA prepared from an enriched source of documented infectious NANB particles passaged in chimpanzees, but originating in an infected human. Clones PT'2, PT'8 and PT'9 also hybridized specifically to cDNA prepared from the NANB-infected chimpanzee.

Example 4

Infection of Immortalized Liver Cells

With NANB Virus

Hybrid liver cells were plated at 1×10^6 cells/well in a 24-well tray and overlaid with 100 μl of plasma from a chimpanzee known by its passage into a second chimpanzee to contain NANB viral agent(s); or (b) human plasma from an individual with acute post-transfusion NANB hepatitis. After an initial incubation of the chimpanzee serum and cells, 0.5 ml of growth medium containing IMDM and 20% FCS was added to

each well and the cells were grown at 37°C in a humidified 7% CO₂ incubator. The cultures were fed with growth medium every 3 to 4 days, and liver hybrid cells were removed every week to assay for the presence of NANB.

To detect the presence of virus particles, the cells were analysed for expression of NANB virus specific surface antigens. The method is as follows: An aliquot of the culture medium containing about 1 x 10⁷ cells was removed from a culture well and the cells pelleted by centrifugation at 200 x g for 10 minutes. After washing the cells three times with PBS, the cells were resuspended to 2.5 x 10⁶ cells/ml and 10 ul of the cell suspension were dropped on a microscope slide and allowed to air-dry. The dried cells were then fixed on the slide by addition of acetone for one minute. To minimize non-specific binding, the slides were preincubated with normal goat serum (1:10 dilution) for 30 minutes at room temperature in a moist chamber. The slides were washed three times with PBS and once with distilled water, then 70 ul of test serum obtained from one of the panel chimpanzees (identified at the left in Table 2, see below) were added to the slides. Each serum sample had been preabsorbed with uninfected liver hybrid cells (10⁷ cells per ml serum) to remove serum factors which tended to bind to the cells non-specifically. The slides containing the added serum were incubated in moist chambers for 90 minutes at room temperature, then again washed three times with PBS and once with distilled water.

Goat anti-human IgG and IgM conjugated with fluorescein isothiocyanate (FITC-conjugated antibody) were obtained from a commercial source (Zymed Labs). They were each diluted with PBS to a final concentration of about 1 ug antibody/ml. Either anti-IgM or anti-IgG FITC-conjugated antibody (70 ul) was added to the washed cells, and the slides were incubated at room

temperature for 30 minutes. After washing with PBS and distilled water as above, the slides were mounted with one drop of 50% glycerol in PBS and observed under a fluorescence microscope. The cells were scored for
 5 weak (+), intermediate (++), and strong (+++) fluorescence.

The first indications of immunofluorescence occurred at about 6 to 8 weeks after initial cell infection with each virus source. The results shown in
 10 Table 2 were obtained 6 weeks post infection with chimpanzee plasma known to contain NANB agent(s).

Table 2

15

Expression of NANB Viral Cell Surface Antigens
 in Immortalized Liver Cells Infected with NANB Virus

| 20 | <u>Chimpanzee</u> | <u>Disease</u> | <u>Reactivity with Liver Hybridomas</u> | |
|----|-------------------|------------------|---|-------------------|
| | | | <u>Infected</u> | <u>Uninfected</u> |
| | A | convalescent HAV | - | - |
| | B ¹ | normal | - | - |
| | B | acute NANB | + | - |
| | C | normal | - | - |
| 25 | D ¹ | normal | - | - |
| | D | acute NANB | ++ | - |
| | E | normal | - | - |
| | F | convalescent HBV | - | - |
| | G | chronic NANB | +++ | - |
| | H | chronic NANB | - | - |

30 ¹ These animals are pre-NANB inoculation.

As seen in the right hand columns in Table 2,
 35 specific immunofluorescence was observed only with serum from NANB-infected animals, and not with serum from uninfected animals or those infected with HBV.

The results indicate that (a) the liver hybrid cells are infectable by NANB virus, (b) the infected hybrid cells are expressing a virus-specific surface antigen which is recognized by NANB serum antibody from chimps
5 with known NANB infection, and (c) an incubation period of between about 4 to 6 weeks is required for surface antigen expression.

The results shown in Table 2 were obtained with anti-IgG antibody. No immunofluorescence was
10 observed with FITC-conjugated anti-IgM antibody, as would be expected if the chimpanzee anti-NANB antibodies were IgG antibodies. Plasma from a patient with acute post-transfusion NANB gave a result similar to those obtained above with plasma from infected chim-
15 panzees. After 6 weeks, liver hybrids infected using patient plasma showed specific immunofluorescence with serum from a NANB-infected chimpanzee, but not with control (uninfected) chimpanzee serum.

20

Example 5

Recovery of NANB Infectious Virus Particles from Hybrid Liver Cells

The NANB-infected hybrid cells were also examined for the presence of infectious virus.
25 Infected hybrid cells (obtained as described in Example 4) 12 weeks post infection were collected by centrifugation, then washed three times with PBS. The cells were resuspended in PBS to about 5×10^6 cells/ml and sonicated to clarity. The supernatants (0.5 ml/well)
30 were then inoculated on uninfected hybrids and cultured in the manner described in Example 4 for cell infection by chimpanzee plasma. Cell-free lysates can also be prepared by hypotonic lysis or freeze-thawing. After about 6 to 8 weeks in continuous culture, specific
35 immunofluorescence was observed with chimpanzee NANB serum, but not with serum from uninfected animals,

demonstrating that the cell particles so propagated retained their infectivity.

Example 6

5 Stability of Viral Infectivity of NANB Virus Particles Propagated in Hybrid Liver Cells

 Molecular clones from NANB-infected cells are isolated to determine if in vitro passage leads to the generation of defective viral particles, with resultant
10 attenuation of viral infectivity. The method is as follows:

 Infected cells are grown in exponential phase and then harvested by centrifugation for 10 minutes at 3,000 rpm. A cell-free lysate is prepared from 5×10^8
15 cells by 3 successive cycles of freezing on dry ice/ethanol and thawing at room temperature. The lysate is clarified by centrifugation at $10,000 \times g$ for 15 minutes in a microfuge. The supernatant is then loaded onto a linear sucrose density gradient as
20 described above (see Example 2). The fractions having a buoyant density of from 1.09 to 1.11 gm/cm^3 are collected and particles extracted for RNA as described above in Example 3. After conversion to cDNA, and amplification as described in Example 3, the amplified
25 cDNA is analysed by Southern blot hybridization to confirm the presence of NANB homologous sequences. The probes used are the cDNA clones whose sequence appears in Figures 1 to 4. The material is then cloned into λ gt10 and molecular clones selected by hybridization
30 using the molecular clones shown in Figures 1 to 4 as a probe. The primary nucleotide sequence of molecular clones derived from infected hybrid liver cells is then analysed to determine whether defective viral particles have been generated during passage in vitro.

35

 All publications and patent applications mentioned in this specification are indicative of the

level of skill of those skilled in the art to which
this invention pertains. All publications and patent
applications are herein incorporated by reference to
the same extent as if each individual publication or
5 patent application was specifically and individually
indicated to be incorporated by reference.

The invention now being fully described, it
will be apparent to one of ordinary skill in the art
that many changes and modifications can be made thereto
10 without departing from the spirit or scope of the
appended claims.

15

20

25

30

35

WHAT IS CLAIMED IS:

1. A hybrid cell comprising:
non-A, non-B (NANB) viral genomic
5 material, said cell being produced by the method
comprising:
infecting said hybrid cell with a sample
comprising infectious NANB virus particles.
- 10 2. The hybrid cell according to Claim 1,
wherein said infectious virus particles have a buoyant
density of about 1.09 to about 1.11 gm/cm³.
- 15 3. A method for propagating non-A, non-B
hepatitis (NANB) viral genomic material, said method
comprising:
growing a hybrid cell line infected with
NANB viral genomic material for a sufficient time for
said viral genomic material to propagate.
- 20 4. The method according to Claim 3, wherein
said cell line is infected by contacting uninfected
hybrid cells with a sample comprising infectious NANB
virus particles.
- 25 5. The method according to Claim 4, wherein
said sample comprises :
virus particles and antigens associated
with non-A, non-B hepatitis separated from contaminants
30 based upon buoyant density collecting as a non-A, non-B
fraction, material having a buoyant density of about
1.07 to about 1.13 gm/cm³.
- 35 6. The method of Claim 4, wherein said
fraction contains material having a buoyant density of
from about 1.09 to about 1.11 gm/cm³.

7. Virus particles isolated from a biological sample, said virus particles being characterized as being obtainable from cells susceptible to infection with PT-non-A non-B (NANB) hepatitis virus and having a bouyant density of from about 1.09 to 1.11 gm/cm³.

8. The virus particles according to Claim 7, wherein said biological sample is plasma or an hepatocyte from a host infected by PT-NANB hepatitis virus.

9. The virus particles according to Claim 8, wherein said host is human.

10. The virus particles according to Claim 7, wherein said particles are further characterized as having an RNA viral genome comprising a sequence at least 80 percent homologous to a sequence of at least 12 consecutive nucleotides within one of the following DNA sequences:

| | | |
|----|--|-----|
| 1 | ACACAACCAAATTCTTGGTTCCAGCGCCAACCTGAAACCAAA | 42 |
| 43 | AAAGTGGCAAATATTGCCGGGCAAGCGTCGATTGCTTCGACC | 84 |
| 25 | 85 GCCTATGTGAGCCAAGATGCGGCCATTTCCGGCCTACAATAAA | 126 |
| | 27 GTAAAAAATGCTGTGGTCACCGTGCAAACTTGCAAAAGAAT | 168 |
| | 169 GCGGCCCAAACCCCAGATGGTTTTGCGGGGTGTTTGGTCAA | 210 |
| | 211 TCAGGGCGTCAAAAGCAAGCCGATAATAATGGCCAAGTTGAA | 252 |
| 30 | 253 ACTGCCTCAGAAGGCTCT | 270 |

or

| | | |
|----|---|-----|
| 1 | AAAAATAACAAGATCTTACATTTACGGAAATCTGCGACAAAA | 42 |
| 35 | 43 GTTTCCAAATATAAGATCAAAAAGTTAAGTGTGGTGTGCGCC | 84 |
| | 85 TCCGTTCTGGTGGGGGCCACTTCTTCCTTGGTTCGACAGCG | 126 |

127 AGTGCAAGTGCTTCTGATGAGCAACTCGCTGATAAGCAGGCA 168
169 GGGGTCACACAACAACTGATCAAAATGCAACAAACACAAAT 210
211 GATCGGGTATTAAAGTTTGACAATGCAACGTCAACGGCCACA 252
253 ACGGATAATGCTGATTCTAGTGCGGCCAAAATGTCAAACGTT 294
295 GCGCAAGCTGACAATTCAGCCAACAATGCAACAGTAGCTAAT 336
337 AATCTTGATAAAAAATCAATTACCGATTCTACATTATCCAAT 378
379 AATAACGATTTAAAATCAACTGAAATGCAATCAACTGTTACT 420
421 GACCAAGCAGCAGCTGACGATGCAAGTACTGCTGATCAAACA 462
463 GCAACTGAAAAGCAAGCAACTGTGACCAATCAAGCCACAGTT 504
505 GATAACACAGTAAATACTGCTGACCAAGCAACTCAAGCAGCA 546
547 GCTGAAAAGACAACAACGCCTGCAAGTACTGCTGCCAACACG 588
589 CAAGCAGCTGCACTAGTTGCAACGCTACGTGCCGCAGCAACT 630
631 GCGGATACAAGTACGACGACAACGTGTTAACAACCTGGACT 669

or

1 CCATCGGCTTCCATCCAGGAAGCAATGGATAAGCAGTTAACG 42
43 GCTGATCGTGAACGAGTGGCAACTATTGCAAAAGCCGAAGGG 84
85 GAGGCACGCTCCATCGAACTCACAACCAAGGCTAAAAATGAC 126
127 GCGTTGATGGCGACGGCGAAAGCCGAAGCTGACGCGACGAAA 168
169 ACCCGTGCTGATGCCGAACGTTACCGAATCGATACGGTACAA 210
211 GCTGGTTTGGCTGGGGCGGATGACAAGTACTTCCAAAACCAA 252
253 TCCATTAACGCATTTCGCGACGTTACCCAAT 282

or

ATCGAGAGCAACGCACTGGCAGTGTCCAACCTGGATTTCTGATC
CTGTTTTGACCCGCAGTACCCAAAAAGGCCAACGCTCAGCGTTGGCCTTT
TTTAATGGCTAAAAAATGACTATGGCGCCAACAGCACCGCCCTCTCCTCG
CGGCACAACTCCAGTAAAAAATCCCACACCACCCTCAACCTTACGGATTT
GTGCAGTTCCCGGCGGGTGCTGATCCAGTAACTGCGTTGCACAGACTCGC
CCGGCAATACACGCACCAGGTCGGGGTCGTCAGCGGCCATGTAGTTGGGC

AATACGGCGATACCCAGGCCGGCGGAGCGGCTTGTTGCTGGGCAATGAC
GCTGGTGCTGCGAAAGGTCACGGTCGGGGTGCGGCAGAAGGTATTGAGGA
ACAGCAGCTCCTGACTGAACAACAGGTCGTCGACGTAGCCGATCCAGTAG
TGGTTGCCA

or

GTCATCACGCACAACAGGGGTGTTGAGCGGTGC
ACCGAGTTCTTTCCAGTCCGGGAACAATTCGTTTCAGCGCACGGGGTTCAA
ACACGGCACCGGACAGGATGTGAGCGCCGACTTCGGAGCCTTTTTTCGACC
ACGCAGACGCTGATTTCTTACCGGCTTCGGCGGCCTTCTGCTTCAATCG
GCAGGCGGCAGACAGGCCTGCCGGGCCAGCGCCGACGATGACCACGTC

or

GTTGACCACTCCCTGGCCGTGGAAGCCGGTG
GTTGACCGACGCCTTCGAGAAGAACCGCGCCATCGAAGACCGCCGCAAC
GAAGACTGTTTCCACTTTATCGAGTGGACCAAAAAGGCCTTCAAGAACGT
CGATGTGATCCGCCGGGCAACGGCATCATGCACCAGATCAACCTGGAGAA
AATGTCGCCGGTGATCCAGGTGCGCGACGGCGTAGCTTCCGGATACCTGC
GTCGGCACCGATAGCCACACGCCCACGTGGATGCCTTGGCGTGATCGCAT
CGGCTCTGGCGCGTA

or

CCCCATAGAGCCCGGACCCATAGACAGCCCTG
CCCCATAGACAGTCTGGCCCTATAGACAGCCAGCCCCATAGAGCCCGGC
CCTATAGATAGCCCGGCCCCATACAGCCCGGACCCATAGAGAGCACTGCC
CCATAGAGCCCGGACCCATAGAGCCCTGCCCCATAGACAGTC

or

GCCAAAGAGTGGCGCACCGACCGTTCCCTCAG
CCGCCTCGAAGCCATGCTCGCCGTGGCCAACAAAGACGCCTCCCTGATCA
TCACCGGCAACGGTGACGTGGTAGAGCCAGAAAACGGCTTGATCGCCATG

GGCTCCGGTGGCGGCTACGCCAGGCTGCGGCCAGTGCGCTGTTGAAGAAA
ACCGACCTGTCGGCCCGTGAAATCGTCGAGACCGCCTTGGGCATCGCTGG
CGATATCTGCGTGTTACCAACCACAACCTGACCATTGAGGAGCAGGACC
TCGCCGAGTAAGCCGTAGGCTTATTC

or

GGCGATGACGGCTGCACCGCAAGCACCAGTA
TCAGTCCAGCCAAGTGAAACAGTGACACCTGCACAACCCGTCAAAGTTGC
ACCACAAGTGGTTGCAGCGCAACCAACGTCAACACCAACACCAACGGTAA
CAGTTGAGACTGTACCATCAACGCCTACGCCAGTGCCACCAACATTGGCA
ACGCCACCAATTGCACAACCAGTGGTAACTGCTGCGCCAACTGAAGAAGC
AGCCGTTGCCAACCAGTTGTGGGCACGTACGGGACAAAATGCGGTCTTTG
CCGTCCTACAACAAGCGAACGGAGACGCTTAGTCGCGTGAAGGCTGCTTG
GTCAGACTTGATTAGTCAATTTGGTGTGCTGAACAGGCCTTACTGACGA
TTGCCGCCCCAGTAGCTGCAAGTGAGGAAGGGCTTGTTTTAGCGTTTGAT
TTTCCACCTTTATTGGCGCAAGCTTTACAAGATGCCGCCTTGCAAACGCA
ATTACGGACAGCGCTGGCTGCACAACAATTGCCAACAGAAATGGTGTGTA
TTACCCAAGATAGCTGGCAACAAGAACGCTCTGATTATGTCGCGCAGTTA
AAGGCGGGGACGACTCAACCTTTGAATTTGGCGGATATACCGAGAGTGAG
CCAAACAACCACGACCCAGTCGCAAAGTGACCGACACCAGAGCAAACGG
GGCTTG

or

TCGGGCCGGTAATGACCACGGCCACCATAGCACCGCGAAGAAGCCTGCGA
TGGCGACGCTGGAGGCCATGGTGACGACGCTCCAATCGATGTCCGCGCGC
GCTCGGCGGCGGATCTGCCGGATATCATCCGGCGCACCAGTCGGACGCC
GCAGCCGCGCTACCGGCCCCGAGAAAGAAGATCGCCGCGCCCATTCGATG
GGGAACG.

11. The virus particles according to Claim 10,
wherein said viral genome comprises a sequence at least

90 percent homologous to a sequence of at least 60 consecutive nucleotides within said sequence.

12. A substantially pure polynucleotide having
5 a region substantially complementary to or the same as a segment of at least 12 consecutive nucleotides of a DNA sequence of Claim 10.

13. The polynucleotide according to Claim 12,
10 wherein said polynucleotide comprises substantially the entire sequence of one of said sequences.

14. A PT-non-A, non-B viral antigen defining
at least one antigenic determinant, said antigen
15 comprising:

a protein encoded in part by a sequence substantially homologous to a DNA sequence of Claim 10 or a complementary sequence.

15. The antigen of according to Claim 14,
20 substantially free of other proteins.

16. A vector comprising a replication system functional in a bacterium, a marker for detection of
25 transformants and a sequence substantially homologous to a sequence of at least 60 nucleotides of a sequence of Claim 10.

17. A method for detecting the presence of a
30 non-A, non-B hepatitis virus, which comprises:
analyzing a biological sample to determine the presence of an analyte, wherein said analyte comprises a nucleotide sequence having a sequence which hybridizes with a probe comprising at least 16
35 consecutive nucleotides of a sequence of Claim 10.

18. A vaccine for immunizing a host against non-A, non-B (NANB) hepatitis viral agent, said vaccine comprising:

5 a viral antigen or an inactivated or attenuated virus particle in a physiologically compatible solution, wherein said antigen or particle is obtained from a cell infected with NANB hepatitis virus.

10 19. The vaccine according to Claim 18, wherein said viral antigen or said virus particle comprises a protein encoded in part by a sequence substantially homologous to a sequence of Claim 10 and wherein said protein defines at least one antigenic determinant.

15 20. The vaccine according to Claim 19, wherein said antigenic determinant is recognized by NANB serum antibody from chimpanzees or humans with known NANB infection.

20 21. An anti-viral agent comprising an antibody composition, wherein said antibodies are capable of binding to a post transfusion non-A, non-B (PT-NANB) hepatitis virus particle, and wherein production of said antibodies is obtained by administering to said host
25 animal an immunogenic composition comprising PT-NANB virus particles isolated from a biological sample, or non-particle antigens native to PT-NANB virus particles, said virus particles being characterized as being obtainable from cells susceptible to infection with PT-
30 NANB.

22. An antiviral agent according to Claim 21, wherein at least a portion of the Fc region of said antibodies has been removed.

35 23. An anti-viral agent according to Claim 21, wherein said production is immortalized by preparation

of a hybridoma cell comprising a cell from said host animal which synthesises said antibodies.

24. An antiviral agent according to Claim 23,
5 wherein said hybridoma is a human-human hybridoma.

25. An antiviral agent according to Claim 24,
wherein said antibodies are monoclonal antibodies.

10 26. A hybridoma producing antibodies capable
of binding to a post transfusion non-A, non-B (PT-NANB)
hepatitis virus particle.

27. A hybridoma according to Claim 26, wherein
15 antibodies are monoclonal antibodies.

28. An anti-idiotypic antibody composition
comprising antibodies having a conformation at least
substantially similar to a native non-A, non-B (PT-NANB)
20 hepatitis virus antigen, wherein production of said
antibodies is obtained by administering to a host animal
an immunogenic composition comprising anti-PT-NANB virus
antibodies.

25 29. A method of enhancing the effectiveness of
an anti-viral drug in a post-transfusion non-A, non-B
(PT-NANB) hepatitis virus-infected host animal treated
with said drug, said method comprising:

treating said host animal with an anti-PT-NANB
30 antibody composition in conjunction with said drug.

30. The method of Claim 29 wherein said
treating comprises inducing said anti-PT-NANB antibody
composition in said host animal by administering to
35 said host animal an anti-idiotypic antibody having a
conformation at least substantially similar to a native
PT-NANB hepatitis virus antigen.

1/7

1 E V T G L V Y N D K D I E N
GAAGTAACAGGACTCGTCTATAACGATAAAGATATCGAAAAT 42

43 V V I Y T A N I Q K A N V T
GTTGTTATCTATACGGCTAATATTCAAAGGCGAATGTGACA 84

85 Y I D D T T G K T L E T H G
TACATTGATGACACAACCTGGTAAACTTTAGAGACACATGGA 126

127 L S G K T G T T D S Y K T S
TTATCAGGTAAGACAGGAACAACAGATAGTTATAAGACTAGT 168

169 D T I T S Y E D K G Y A L V
GATACGATCACATCTTATGAAGATAAGGGTTATGCATTAGTC 210

211 S D N Y P A D G V V Y D N D
AGTGATAACTATCCAGCGGATGGAGTTGTGTATGATAATGAT 252

253 D A V D Q N F E V H L K H T
GACGCTGTTGATCAAACTTTGAAGTACATTTGAAACATACA 294

295 T T T V N P K D P Q T P G E
ACAACCACAGTTAATCCAAAGGACCCACAAACACCAGGGGAA 336

337 P I N P K D P D G P K W P T
CCTATCAATCCGAAGGATCCAGATGGACCAAAGTGGCCAACG 378

379 G T D A D S L T E T V N E T
GGAAGTATGCTGACTCGTTAACAGAACTGTTAATGAGACC 420

421 T H Y
ACTCATTAT 429

Figure 1

2/7

| | |
|--|-----|
| T Q P N S W F Q R Q P E T K | |
| 1 ACACAACCAAATTCTTGTTCCAGCGCCAACCTGAAACCAA | 42 |
| K V A N I A G Q A S I A S T | |
| 43 AAAGTGGCAAATATTGCCGGGCAAGCGTCGATTGCTTCGACC | 84 |
| A Y V S Q D A A I S A Y N K | |
| 85 GCCTATGTGAGCCAAGATGCGGCCATTTCCGGCCTACAATAAA | 126 |
| V K N A V V T V Q N L Q K N | |
| 127 GTAAAAAATGCTGTGGTCACCGTGCAAACTTGCAAAAGAAT | 168 |
| A A Q T P D G F A G L F G Q | |
| 169 GCGGCCCAAACCCAGATGGTTTTGCGGGGTGTTTGGTCAA | 210 |
| S G R Q K Q A D N N G Q V E | |
| 211 TCAGGGCGTCAAAAGCAAGCCGATAATAATGGCCAAGTTGAA | 252 |
| T A S E G S | |
| 253 ACTGCCTCAGAAGGCTCT | 270 |

Figure 2

3/7

| | | |
|-----|---|-----|
| 1 | K N N K I L H L R K S A T K AAAAATAACAAGATCTTACATTTACGGAAATCTGCGACAAAA | 42 |
| 43 | V S K Y K I K K L S V G V A GTTTCCAAATATAAGATCAAAAAGTTAAGTGTGGTGTCGCC | 84 |
| 85 | S V L V G A T F F L G S T A TCCGTTCTGGTGGGGGCCACTTTCTTCCTTGGTTCGACAGCG | 126 |
| 127 | S A S A S D E Q L A D K Q A AGTGCAAGTGCTTCTGATGAGCAACTCGCTGATAAGCAGGCA | 168 |
| 169 | G V T Q Q T D Q N A T N T N GGGGTCACACAACAACTGATCAAAATGCAACAAACACAAAT | 210 |
| 211 | D R V L K F D M A T S T A T GATCGGGTATTAAAGTTTGACAATGCAACGTCAACGGCCACA | 252 |
| 253 | T D N A D S S A A K M S N V ACGGATAATGCTGATTCTAGTGCGGCCAAAATGTCAAACGTT | 294 |
| 295 | A Q A D N S A N N A T V A N GCGCAAGCTGACAATTCAGCCAACAATGCAACAGTAGCTAAT | 336 |
| 337 | N L D K K S I T D S T L S N AATCTTGATAAAAAATCAATTACCGATTCTACATTATCCAAT | 378 |
| 379 | N N D L K S T E M Q S T V T AATAACGATTTAAAATCAACTGAAATGCAATCAACTGTTACT | 420 |
| 421 | D Q A A A D D A S T A D Q T GACCAAGCAGCAGCTGACGATGCAAGTACTGCTGATCAAACA | 462 |
| 463 | A T E K Q A T V T N Q A T V GCAACTGAAAAGCAAGCAACTGTGACCAATCAAGCCACAGTT | 504 |
| 505 | D N T V N T A D Q A T Q A A GATAACACAGTAAATACTGCTGACCAAGCAACTCAAGCAGCA | 546 |
| 547 | A E K T T T P A S T A A N T GCTGAAAAGACAACAACGCCTGCAAGTACTGCTGCCAACACG | 588 |
| 589 | Q A A A L V A T L R A A A T CAAGCAGCTGCACTAGTTGCAACGCTACGTGCCGCAGCAACT | 630 |
| 631 | A D T S T T T T V N N W T GCGGATACAAGTACGACGACAACCTGTTAACAACCTGGACT | 669 |

Figure 3

417

| | | |
|-----|--|-----|
| | P S A S I Q E A M D K Q L T | |
| 1 | CCATCGGCTTCCATCCAGGAAGCAATGGATAAGCAGTTAACG | 42 |
| | A D R E R V A T I A K A E G | |
| 43 | GCTGATCGTGAACGAGTGGCAACTATTGCAAAAGCCGAAGGG | 84 |
| | E A R S I E L T T K A K N D | |
| 85 | GAGGCACGCTCCATCGAACTCACAACCAAGGCTAAAAATGAC | 126 |
| | A L M A T A K A E A D A T K | |
| 127 | GCGTTGATGGCGACGGCGAAAGCCGAAGCTGACGCGACGAAA | 168 |
| | T R A D A E R Y R I D T V Q | |
| 169 | ACCCGTGCTGATGCCGAACGTTACCGAATCGATACGGTACAA | 210 |
| | A G L A G A D D K Y F Q N Q | |
| 211 | GCTGGTTTGGCTGGGGCGGATGACAAGTACTTCCAAAACCAA | 252 |
| | S I N A F A T L A N | |
| 253 | TCCATTAACGCATTCGCGACGTTACCCAAT | 282 |

Figure 4

5/7

Sequence 1: clone 385-11-5

ATCGAGAGCAACGCACTGGCAGTGTCCAACCTGGATTCTGATC
CTGTTTTGACCCGCAGTACCCAAAAAGGCCAACGCTCAGCGTTGGCCTTT
TTTAATGGCTAAAAAATGACTATGGCGCCAACAGCACCGCCCTCTCCTCG
CGGCACAACCTCCAGTAAAAAATCCACACCACCCTCAACCTTACGGATT
GTGCAGTTCCTGGCGGGTGCTGATCCAGTAACTGCGTTGCACAGACTCGC
CCGGCAATACACGCACCAGGTCGGGGTCGTCAGCGGCCATGTAGTTGGGC
AATACGGCGATACCCAGGCCGGCGCGAGCGGCTTGTTGCTGGGCAATGAC
GCTGGTGCTGCGAAAGGTCACGGTCGGGGTGCGGCAGAAGGTATTGAGGA
ACAGCAGCTCCTGACTGAACAACAGGTCGTCGACGTAGCCGATCCAGTAG
TGGTTGCCA

Sequence 2: clone 385-16-2

GTCATCACGCACAACAGGGGTGTTGAGCGGTGC
ACCGAGTTCTTTCCAGTCCGGGAACAATTCGTTTCAGCGCACGGGGTTCAA
ACACGGCACCGGACAGGATGTGAGCGCCGACTTCGGAGCCTTTTTCGACC
ACGCAGACGCTGATTTCTTACCGGCTTCGGCGGCCTTCTGCTTCAATCG
GCAGGCGGCAGACAGGCCTGCCGGGCCAGCGCCGACGATGACCACGTC

6/7

Sequence 3: clone 385-2-14

GTTGACCACTCCCTGGCCGTCGAAGCCGGTG
GTTGACCGACGCCTTCGAGAAGAACCGCGCCATCGAAGACCGCCGCAAC
GAAGACTGTTTCCACTTTATCGAGTGGACCAAAAAGGCCTTCAAGAACGT
CGATGTGATCCGCCGGGCAACGGCATCATGCACCAGATCAACCTGGAGAA
AATGTCGCCGGTGATCCAGGTGCGCGACGGCGTAGCTTCCGGATACCTGC
GTCGGCACCGATAGCCACACGCCCACGTGGATGCCTTGGCGTGATCGCAT
CGGCTCTGGCGCGTA

Sequence 4: clone 385-20-1

CCCCATAGAGCCCGGACCCATAGACAGCCCTG
CCCCATAGACAGTCTGGCCCTATAGACAGCCAGCCCCATAGAGCCCGGC
CCTATAGATAGCCCGGCCCCATACAGCCCGGACCCATAGAGAGCACTGCC
CCATAGAGCCCGGACCCATAGAGCCCTGCCCCATAGACAGTC

Sequence 5: clone 386-8-1

GCCAAAGAGTGGCGCACCGACCGTTCCTCAG
CCGCCTCGAAGCCATGCTCGCCGTGGCCAACAAAGACGCCTCCCTGATCA
TCACCGGCAACGGTGACGTGGTAGAGCCAGAAAACGGCTTGATCGCCATG
GGCTCCGGTGGCGGCTACGCCAGGCTGCGGCCAGTGCGCTGTTGAAGAAA
ACCGACCTGTCGGCCCGTGAAATCGTCGAGACCGCCTTGGGCATCGCTGG
CGATATCTGCGTGTTACCAACCACAACCTGACCATTGAGGAGCAGGACC
TCGCCGAGTAAGCCGTAGGCTTATTC

Figure 5

(Page 2 of 3)

7/7

Sequence 6: clone D20

GGCGATGACGGCTGCACCGCAAGCACCAGTA
TCAGTCCAGCCAAGTGAAACAGTGACACCTGCACAACCCGTCAAAGTTGC
ACCACAAGTGGTTGCAGCGCAACCAACGTCAACACCAACACCAACGGTAA
CAGTTGAGACTGTACCATCAACGCCTACGCCAGTGCCACCAACATTGGCA
ACGCCACCAATTGCACAACCAGTGGTAACTGCTGCGCCAACCTGAAGAAGC
AGCCGTTGCCAACCAGTTGTGGGCACGTACGGGACAAAATGCGGTCTTTG
CCGTCCTACAACAAGCGAACGGAGACGCTTAGTCGCGTGAAGGCTGCTTG
GTCAGACTTGATTAGTCAATTTGGTGTTGCTGAACAGGCCTTACTGACGA
TTGCCGCCCCAGTAGCTGCAAGTGAGGAAGGGCTTGTTTTAGCGTTTGAT
TTTCCACCTTTATTGGCGCAAGCTTTACAAGATGCCGCCTTGCAAACGCA
ATTACGGACAGCGCTGGCTGCACAACAATTGCCAACAGAAATGGTGTGTA
TTACCCAAGATAGCTGGCAACAAGAACGCTCTGATTATGTCGCGCAGTTA
AAGGCGGGGACGACTCAACCTTTGAATTTGGCGGATATACCGAGAGTGAG
CCAAACAACCACGACCCAGTCGCAAAGTGCACCGACACCAGAGCAAACGG
GGCTTG

Sequence 7: clone S14

TCGGGCCGGTAATGACCACGGCCACCATAGCACCGCGAAGAAGCCTGCGA
TGGCGACGCTGGAGGCCATGGTGACGACGCTCCAATCGATGTCCGCGCGC
GCTCGGCGGCGCGATCTGCCGGATATCATCCGGCGCACCAGTCGGACGCC
GCAGCCGCGCTACCGGCCCCGAGAAAGAAGATCGCCGCCGCCCATTCGATG
GGGAACG

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US89/02817

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC
IPC(4): C12N 7/00, 5/00, 1/00; C12Q 1/70, 1/68; GOIN 33/535; C07H
15/12; A61K 37/02, 37/04; C07K 13/00; C07G 7/00; C07K 7/00.

II. FIELDS SEARCHED

| Minimum Documentation Searched * | |
|----------------------------------|---|
| Classification System | Classification Symbols |
| U.S | 435/235, 240.26, 240.27, 5, 6, 7, 320; 536/27 424/88, 85.8; 530/387, 350, 300. |

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *

Chemical Abstracts Data Base (1967-1975) Keywords: Non-A Non-B
hepatitis; virus; particle; sequence

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

| Category * | Citation of Document, ** with indication, where appropriate, of the relevant passages ** | Relevant to Claim No. ** |
|----------------------------|--|--|
| A | Chemical Abstracts, volume 103, no. 13, issued 30 September 1985 (Columbus, Ohio USA) Miyamura, T. "Non-A, non-B hepatitis agent", Kan, Tan, Sui, 10 (1), 25-8; 102993p, p 457. | 1-30 |
| <u>P, X</u> <u>P, Y</u> | Science, volume 244, no 4902. issued 21 April 1989, Kuo, G. "An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis", p362-364. See entire document. | <u>12-16</u> <u>17-30</u> |
| <u>P, X</u> <u>P, Y</u> | Science, volume 244, no. 4902, issued 21 April 1989, Choo, Q; "Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome". p 359-362. See entire document. | <u>12-16</u> <u>17-30</u> |
| <u>P, X</u> <u>P, Y</u> | EP, A, 293274 (Mitsubishi Chemical Industries Co LTD) 30 November 1988. See entire document. | <u>12-16, 21,</u> <u>23, 25-27</u> <u>17-20, 22,</u> <u>24, 29-30</u> |

* Special categories of cited documents: **

- "A" document defining the general state of the art which is not
considered to be of particular relevance
- "E" earlier document but published on or after the international
filing date
- "L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or
other means
- "P" document published prior to the international filing date but
later than the priority date claimed

- "T" later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention
- "X" document of particular relevance: the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step
- "Y" document of particular relevance: the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.
- "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

1 October 1989

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

26 OCT 1989

Signature of Authorized Officer

Anne Brown
Anne Brown

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) | | |
|--|--|-------------------------------------|
| Category * | Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No |
| $\frac{X}{Y}$ | DE, A, 3316464 Seelig, R. et al 8 November 1984. See entire document. | $\frac{7-11}{7-11, 12, 13, 16, 17}$ |
| $\frac{X}{Y}$ | Lancet, volume 2, issued 1984, Seto, B., "Detection of reverse transcriptase activity in association with the non-A non-B hepatitis agents", p 941-943 | $\frac{7-11}{12, 13, 16, 17}$ |
| $\frac{X}{Y}$ | Naturwissenschaften, volume 73, issued 1986, Hakim, A, "Isolation and Functional Property of mRNA coding for hepatitis A, B, and non-A non-B viral particles from human sera", p 45-47. | $\frac{12, 13}{14-17}$ |
| $\frac{X}{Y}$ | EP, A 263761 (Mitsubishi Chemical Industries Co. LTD.) 13 April 1988. See entire document. | $\frac{14-15}{18-30}$ |
| $\frac{X}{Y}$ | JP, A 62/181798 (Mitsubishi Chemical Industries Co. LTD) 10 August 1987. See entire document | $\frac{23, 26, 27}{24, 25, 28-30}$ |
| $\frac{X}{Y}$ | JP, A 61/56196 (Fuji Revio Co. LTD; Mitsubishi Chemical Industries Co. LTD) 20 March 1986. See entire document. | $\frac{23, 26, 27}{24, 25 28-30}$ |
| $\frac{X}{Y}$ | Proc. Natl. Acad. Sci. USA, volume 82, issued 1985, Seto, B, "A glycoprotein associated with the non-A non-B hepatitis agents; isolation and immunoreactivity", p 4934-4938. See entire document. | $\frac{14, 15}{18-30}$ |
| P, X | Chemical Abstracts, volume 110, no 11, issued 13 March 1989 (Columbus, Ohio, USA) Seelig, R et al "Cloning and Sequencing of the non-A, non B hepatitis viral genome" EP 279460 A1 24 August 1988; p 211, 88905 j. | $\frac{7-21}{22-30}$ |

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category * | Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No |
|------------|--|----------------------|
|------------|--|----------------------|

| | | |
|---------------|--|--|
| P,A | Chemical Abstracts, volume 111, no.3 issued 17 July 1989 (Columbus, Ohio USA) Arima T. "Cloning of blood borne non-A non-B hepatitis virus". Jikken Igaku, vol 7(2) p196-201. 18385Z, p139 | 1-30 |
| $\frac{X}{Y}$ | US,A, 4,673,634 (United States of America Dept. of Health and Human Services) 16 June 1987 See entire document. | 14,15,7-11, 18-21 20-30,12,13 16,17 |
| X | US,A,4,707,439 (United States of America Dept. Health and Human Services) 17 November 1987. See columns 2-6. | 7-11 12,13,16, 17 |
| $\frac{X}{Y}$ | US,A, 4,702,909 (Louisiana State University A+M) 27 October 1987. See entire document. | 14,15,7-11 18-21 12,13,16,17 22-30 |
| $\frac{X}{Y}$ | US,A,4,464,474 (Connaught Laboratories LTD) 7 August 1984 | 3-11,14,15 18-21 12,13,16,17 22-30 |
| $\frac{X}{Y}$ | WO,A, 87/05930 (Genelabs Inc.) 8 October 1987. See entire document. | 1-6,14, 17 7-13,15, 16,18-30 |
| $\frac{X}{Y}$ | FR,A 2606515 (Institut Pasteur) 13 May 1988 See entire document | 7-11,14-15 12,13,16,17 18-30 |
| X | EP,A 154392 (Warner Lambert) 11 September 1985. See entire document. | 21 |
| $\frac{X}{Y}$ | Chemical Abstracts, volume 105, no.11, issued 15 Sept. 1986 (Columbus Ohio USA) Spertini, O. "Biophysical properties and morphology of purified antigen associated with non-A non-B hepatitis. Med. Microbiol. Immunol. 175(4), 229-39; 95724n, p 485. | 7-11,14,15 12,13,16,17 18-30 |

Attachment to Section VI

- I. Claims 1-6 are drawn to infected cells, process of making the cells, and process of using the cells.
- II. Claims 7-11 and 18-20 are drawn to virus particles and a vaccine containing particles.
- III. Claims 12, 13, 16, 17 are drawn to a polynucleotide, a vector containing it and a process of using it.
- IV. Claims 14, 15, and 18-20 are drawn to a peptide antigen and a vaccine containing the antigen.
- V. Claims 28 and 30 are drawn to an anti-idiotypic antibody and a method of using it.
- VI. Claims 21, 22, 29, and 30 are drawn to a natural antibody and methods of using and producing it.
- VII. Claims 23-27 and 29 are drawn to hybridomas, antibodies from hybridomas, and methods of using the antibodies.

The claims do not embrace one single general inventive concept as defined in Rule 13.

Groups I-VII contain claims directed to distinct chemical entities. These are cells, particles, polynucleotide, peptide antigen, anti-idiotypic antibody, natural antibody, hybridoma-derived antibody and hybridoma.